Co-Clinical Trials Demonstrate Superiority of Crizotinib to Chemotherapy in <i>ALK</i> -Rearranged Non–Small Cell Lung Cancer and Predict Strategies to Overcome Resistance

Abstract

Our findings suggest that crizotinib is superior to standard chemotherapy in ALK inhibitor-naïve disease and support further clinical investigation of HSP90 inhibitors and second-generation ALK inhibitors in tumors with primary or acquired crizotinib resistance.